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Introduction
The mitochondrion is an essential cellular organelle with three 
major biological functions: producing most of the cellular 
energy, generating endogenous reactive oxygen species (ROS), 
and regulating programmed cell death (apoptosis).1 It has its 
own genome (mtDNA) maintained in multiple copies, which 
replicates and inherits independently of the nuclear genome 
with a maternal-inherited pattern. The mtDNA is a hotspot 
for mutations because of poor fidelity of mitochondria DNA 
polymerase, high level of endogenous ROS, and lack of effec-
tive mtDNA repair mechanisms.2 Mutations in mtDNA 
have been linked to mitochondrial dysfunction, deregulation 
of apoptosis, and many diseases, including cancers.3,4 Both 
germline and somatic mutations are frequently observed in 
various carcinomas of breast, stomach, liver, prostate, kidney, 
bladder, head and neck, and lung cancer.5–7 Furthermore, 
in vitro studies of transferring a known pathogenic mtDNA 
mutation into a cell line with depleted mtDNA demonstrate 
increased tumorigenicity.8–10
Lung cancer is the leading cause of cancer related mortal-
ity worldwide.11 Although scientific advances in cancer pre-
vention, early detection, and treatment have been made in the 
past decades, the general prognosis for lung cancer remains 
poor, and many environmental and molecular determinants 
of lung cancer prognosis have not been assessed fully. Survival 
rates for lung cancer are generally lower than those for most 
cancers, with an overall five years survival rate for lung cancer 
of about 17%.12 In the United States, over 80% of lung cancer 
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cases are classified as non-small cell lung cancer (NSCLC).13,14 
Previous studies revealed that about 43% of lung cancers had 
mtDNA mutations,15 and late stages (IIIB and IV) NSCLC 
had a significantly higher mutation rate than that of early 
stages.16 By sequencing the whole mtDNA genomes of tumor 
tissues, non-affected adjacent tissues, and peripheral blood 
samples from 55 lung cancer patients, Jin et al. did not find 
any association between mtDNA mutations and gender, age at 
diagnosis, smoking history, tumor type, or tumor stage.17 To 
date, however, the impact of mtDNA mutations on the clini-
cal outcomes of NSCLC has not been evaluated.
In this study, we discovered all mtDNA variations in a 
set of NSCLC tissues from Korean patients by whole mtDNA 
resequencing and assessed the association of mtDNA varia-
tions with clinical outcomes. Furthermore, we identified pat-
terns of mtDNA variations and investigated the associations 
between these patterns and clinical outcome, in particular 
survival. Corresponding tumors and matched blood samples 
were also examined from a subset of patients to examine the 
relationship of germline and somatic mutations.
Methods
study population. Since 1995, patients with histologi-
cally confirmed NSCLC were recruited at Samsung Medical 
Center (SMC), Seoul, Korea. The study was approved by the 
institutional review board, and was conducted in accordance 
with the principles of the Declaration of Helsinki. Demo-
graphic information (including age, sex, and smoking sta-
tus) was collected at the time of recruitment, and informed 
consent was obtained to collect follow-up data. Overall sur-
vival (OS) was the end point in this analysis, which was cal-
culated from date of diagnosis to date of death or date last 
known alive. Data were collected from SMC inpatient and 
outpatient records, database from Korea National Statistical 
Office, and direct patient or family contact.
sample collection and dNA isolation. Tumor speci-
mens were collected from patients who underwent surgical 
resections. After examined by pathologists to remove 
the necrotic region and the intervening stroma according to 
the World Health Organization histopathological criteria, the 
specimens were snap frozen and maintained in liquid nitrogen. 
Frozen tissues were micro-dissected under a standard dissect-
ing microscope and lightly stained with hematoxylin to iden-
tify the portion consisting of 90% or more cancer cells. DNA 
samples were isolated using DNeasy kit (Qiagen) according to 
manufacturer suggested protocol. In addition, peripheral lym-
phocytes were collected from a subset of 64 patients and DNA 
samples were extracted using the same kit.
Mitochondrial genome resequencing. Whole mito-
chondrial genomes were sequenced by Affymetrix GeneChip® 
Human Mitochondrial Resequencing Array 2.0 array 
(MitoChip), according to the manufacturer suggested proto-
cols.18 For the hypervariable regions I and II that contain the 
monomorphic stretches, particularly in the regions 67–380 and 
16060–16380, the sequences were further validated by capil-
lary sequencing using ABI3730 after amplified by PCR primers 
HV1F (5’-caccattagcacccaaagct-3’), HV1R (5’-gaggatggtggt-
caagggac-3’), HV2F (5’-ctcacgggagctctccatgc-3’), and HV2R 
(5’-ctgttaaaagtgcataccgcca-3’).
detection of mitochondrial mutations. We car-
ried out mtDNA analysis as previously described.19 Briefly, 
the raw image data of Mitochip were initially processed into 
sequence data by Affymetrix Sequence Analysis Software 
4.1, an ABACUS algorithm based software, according to the 
manufacturer suggested procedures. The sequence data were then 
analyzed by the Sequencing analysis 5.2 (Applied Biosystems, 
USA), Sequence Scanner (Applied Biosystems, USA), Chro-
masPro (Technelysium Pty. Ltd.), and BioEdit (version 7.0.9). The 
mtDNA variations were identified by comparing with the reference 
mtDNA sequence (rCRS: Revised Cambridge Reference Sequence 
of the Human Mitochondrial DNA; GenBank: NC_012920). 
Insertions and deletions in the hypervariable regions I and II were 
determined by aligning 478 redundant fragments on the MitoChip 
with the public database (http://code.open-bio.org) as previ-
ously described.20 As the low prevalence of heteroplasmy could 
not be differentiated from technical errors, only the homoplasmy 
data were used to determine the somatic mutations. For matched 
samples, somatic mtDNA mutations were evaluated by comparing 
mtDNA sequences of the tumor cells with those of the matched 
normal lymphocytes.
statistical analysis. Demographic, clinical, and mtDNA 
variation data were compared using Fisher’s exact and stu-
dent t-tests. The log-rank test was used as a univariate mea-
sure of association between mtDNA variation/haplogroup and 
the clinical outcomes of NSCLC. Cox proportional hazards 
models were implemented to investigate how each of these 
variations/haplogroups impact clinical outcomes in a setting 
in which other clinical and environmental factors, including 
age, gender, smoking status (ever vs. never), histological type, 
and degree of tumor differentiation, may modify the molecular 
impact. For each series of Cox proportional hazards models, 
the allele(s) of the rCRS was used as the reference. All statisti-
cal testing were conducted at the 0.05 level using SAS software 
Version 9.1 (SAS Institute, Cary, North Carolina, USA).
The distributions of mtDNA variations within functional 
locations were evaluated by a modified hypergeometric distri-
bution test.21 The mitochondrial functional locations (includ-
ing encoded genes) are defined by MITOMAP (http://www.
mitomap.org), last edited on 18 August 2009. Variations reported 
in Human Mitochondrial Genome Database (mtDB, http://
www.genpat.uu.se/mtDB/) were used as population controls.
We used dChip software (http://biosun1.harvard.edu/
complab/dchip/) to conduct unsupervised hierarchical cluster-
ing to search any genetic substructure of mtDNA variations.
results
Patient characteristics. All samples were collected 
from NSCLC patients treated with surgical resection at 
mtDNA variations and lung cancer survival
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Samsung Medical Center, Seoul, South Korea. Excluding 
one patient under 18 years old, there were 250 NSCLC 
patients; 100 (40%) patients had died at the time of analy-
sis. The median follow-up time among censored observa-
tions was 36 months (range 7–180 months). Demographic, 
tumor, and treatment characteristics are listed in Table 1. 
Majority of the patients are males, corresponding to high 
prevalence of male smokers in Asian population. As many 
late-stage (III and IV) patients were not suitable for surgery 
181 of 250 samples (72.4%) were collected from the early-
stage patients (I and II).
Mitochondrial genome variations of lung cancer. The 
Affymetrix MitoChip 2.0 array covers 16,544 bp of human 
mitochondrial genome from position 13 to 16,557. We 
obtained high quality sequencing data, defined as sequenc-
ing calls from more than 90% samples, at 16,055 (97%) 
nucleotide positions, and the minimum completeness rate of 
DNA samples was 99.2%. After the alignment of redundant 
probes and sequence comparison with the rCRS, we identified 
902 mtDNA single nucleotide substitutions or single nucle-
otide insertions/deletions (indels), with seven variations being 
complete nucleotide substitutions and 15 variations having 
variant alleles over 50% of samples in the Korean population. 
The indels included seven single nucleotide deletions and six 
single nucleotide insertions in this population. Addition-
ally, there were 228 mtDNA variations with minor variant 
frequency 2%, including 223 single nucleotide substitutions 
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figure 1. Genome view of mtDna variations in nsCLC samples.  
Notes: the x-axis is the mitochondrial genome location with functional locations (including encoded genes) marked above. functional locations are 
defined by MITOMAP (http://www.mitomap.org), last edited on 18 August 2009. Functional locations less than 20 bp and coding sequences for 22 tRNAs 
(58–74 bp), which are scattered between other encoded genes, were not shown. Left-side y-axis is the P-value of hypergeometric distribution test of 
the variations distributed within functional locations. Variations reported in public database mtDB (Human mitochondrial Genome Database http://www.
genpat.uu.se/mtDB/) were used as population controls for hypergeometric distribution test. Positive value of left-side y-axis indicates that there was an 
enrichment of mtDNA variations within a tested location; and negative value indicates that there were fewer variations identified in NSCLC samples. Dash 
line corresponds to P = 0.05. right-side y-axis is the frequency of individual variation in the NSCLC sample set. Blue diamond represents the defining 
variation of haplogroup D/D4, and green triangle represents the defining variation of haplogroup M/N.
Table 1. Patient characteristics.
ChARACTERISTIC No %
Gender
 male
 female
191
59
76.4
23.6
age, median (range) 62 (34–82)
smoking status
 non-smoking
 smoking
90
160
36.0
64.0
Pathological stage
 I
 II
 III
 IV
133
48
60
9
53.2
19.2
24.0
3.6
Histology subtype
 adenocarcinoma
 squamous carcinoma
203
47
81.2
18.8
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and five indels. Among identified variations, 798 (88%) single 
nucleotide variations had been previously reported in mtDB 
(http://www.genpat.uu.se/mtDB/, 2704 mtDNA sequences 
downloaded by 23 March 2010).22 The prevalence of 111 
novel variations was relatively rare in NSCLC samples, and 
none of them had variant frequency above 2%. Although the 
NSCLC variations were distributed throughout mitochon-
drial genome, they were significantly enriched in the control 
region (D-loop) of mtDNA, especially in the hypervariable 
segment 1 and 2 regions, as compared with variations reported 
in mtDB (Fig. 1). Meanwhile, we identified significantly fewer 
variations in mitochondria genes encoding 16S ribosomal 
RNA (MT-RNR2), ATP synthase F0 subunit 6 (MT-ATP6), 
cytochrome C oxidase subunit III (MT-CO3), and NADH 
dehydrogenase subunit 4 (MT-ND4). Only 12 (11%) novel 
variations were located in the control region. Each NSCLC 
tissue sample had multiple mtDNA variations with a median 
of 30 variations (range 17–43), excluding seven complete sub-
stitutions. In this study, our analyses focused on 228 mtDNA 
variations with minor variant frequency 2%.
Association between single mtdNA variation and 
os. In univariate analyses, except for pathological stage 
(P  0.0001), age (P = 0.023), and tumor differentiation 
(P = 0.003), demographic characters, including gender, 
smoking status (ever vs. never), and histological subtypes, 
were not associated with OS of NSCLC (P  0.247 in all 
univariate tests). Smoking was strongly associated with males 
(P  0.0001), histological subtypes (P  0.0001), and tumor 
differentiation (P  0.001). We carried out our analyses 
separately in the early-stage patients (median survival time: 
20.1 months) and late-stage patients (median survival time: 
25.8 months). We identified seven mtDNA variations in 
early-stage samples significantly associated with the worse 
OS in crude and/or adjusted analyses (Table 2). Addition-
ally, we also identified that 13 variations in the early-stage 
sample and 1 variation in the late-stage samples were mar-
ginally associated with OS (0.05  P  0.1). All of these 
mtDNA variations were single nucleotide substitutions, and 
none of the five indel variations was associated with the OS. 
Furthermore, there were high degrees of associations among 
mtDNA variations.
mtdNA variation profiles detected by unsupervised 
hierarchical clustering analysis. Because mtDNA genome is 
small and some of the identified variations were highly corre-
lated, we did not correct multiple comparisons for individual 
mtDNA variation, with the expectation that none of them 
would reach genome-level significance. Instead, we conducted 
a profiling search for substructures of 228 mtDNA varia-
tions using unsupervised hierarchical clustering in the studied 
tumor tissues. The results, which are illustrated in Figure 2, 
were further manually mapped to the mtDNA haplogroups 
in the phylogenetic tree of global human mitochondrial 
DNA variation (http://www.phylotree.org/, mtDNA tree 
build 9, released on 20 June 2010).23 We identified two major 
overlapping substructures. One was the largest substructure 
found in 141 samples with nine variations, which corresponded 
to all defining variations for haplogroup M (T489C, C10400T, 
T14783C, and G15043A) and all defining variations for hap-
logroup N (A8701G, T9540C, A10398G, T10873C, and 
G15301A). The other substructure of mtDNA variations was 
smaller and found in 68 samples; it had six variations corre-
sponding to all defining variations for haplogroup D (C4883T, 
C5178A, and T16362C) and defining variations for haplogroup 
D4 (G3010A, C8414T, and C14668T). The mtDNA substruc-
ture D/D4 was fully embedded within the substructure M/N. 
The combination of two substructures (D/D4/M/N) divided 
the NSCLC samples into three groups, including 68 subjects 
with both substructures (D/D4), 73 samples with only sub-
structure M/N but no D/D4 (M/N-only), and 109 samples 
without variations in either substructures. There were no sig-
nificant differences in the distributions of substructure D/D4, 
substructure M/N-only, and neither D/D4 nor M/N-only 
between the early-stage and the late-stage patients (P = 0.84). 
Moreover, the majority of variations significantly associated 
with the worse OS in early-stage samples (Table 2) were defin-
ing variations of the mtDNA substructures. Furthermore, all 
of the remaining smaller substructures of lung cancer tissues 
identified by unsupervised hierarchical clustering could also 
be mapped to certain mtDNA haplogroups.
We then tested the association between mtDNA sub-
structures and OS. In univariate test, the mtDNA substruc-
ture D/D4 was significantly associated with OS of lung 
cancer in early-stage samples, whereas the combination of 
two substructures (D/D4/M/N) had only marginal associa-
tion (Fig. 3). The substructure M/N-only was not associated 
with OS of lung cancer in early-stage samples (log-rank test: 
P = 0.75). There were similar results in the adjusted model-
ing with D/D4 (adjusted hazard ratio, AHR = 1.95; 95% 
confidence interval, 95% CI: 1.14–3.33; P = 0.033), combina-
tion of two substructures (AHR = 1.44; 95% CI: 1.06–1.96; 
P = 0.034), and M/N-only (AHR = 1.67; 95% CI: 0.97–2.87; 
P = 0.07). When cross-examined with the results of single 
variation analyses, we found that all of the defining mutations 
of the two mtDNA substructures had already been included 
in Table 2.
Variation profiles between tumor tissue and matched 
blood samples. We further compared the mtDNA varia-
tions between NSCLC samples and matched blood samples 
by genotyping 103 variations (including 87 variations used 
in the single variation analysis) on a subset of 64 NSCLC 
patients with matched blood samples. Compared to rCRS, 
we identified a total of 1,651 variations in NSCLC samples 
and matched blood samples. Only 263 (16%) variations 
are somatic mutations in NSCLC samples, which were 
different from the matched blood samples. As illustrated 
in Figure 4, majority of somatic mutations (93%) were 
clustered in 12 patients (19%). Moreover, two major sub-
structures (haplogroups M/N and D/D4), identified by 
mtDNA variations and lung cancer survival
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unsupervised hierarchical clustering, were hotspots for 
somatic mutation, accounting for approximately 39% of the 
total somatic mutations. Although the defining mutations 
of these haplogroups scattered around the entire mitochon-
drial genome, the somatic mutations occurred as turnover 
together at all or majority of these sites. Only one patient 
had a single somatic mutation in haplogroup M/N. Fur-
thermore, somatic turnover occurred in both directions 
with similar prevalence: from the reference alleles of rCRS 
in the blood samples to variant alleles in the tumor samples 
or from variant alleles in the blood samples to the reference 
alleles in the tumor samples.
coexistence of defining variations in mutually exclu-
sive haplogroups M and N. Based on the phylogenetic tree, 
the defining variations of haplogroups M and N are mutu-
ally exclusive. On the contrary, we found the coexistence 
of defining variations of both haplogroups in the studied 
population. We further conducted database queries of 7,843 
entire human mtDNA sequences at PhyloTree.org (updated 
14 August 2010). We selected several studies including 
Asian samples and examined the haplogroups generated by 
SEN-SNiP (http://www.bioinfo.de/isb/2009/09/0026/). By 
checking the reported variations of individual mtDNA 
sample, we could easily identify coexistence of all defining 
variations of both haplogroups M and N in individuals from 
China (eg, mtDNA genome FJ198217.1 and FJ198218.1),24 
India (eg, mtDNA genome AY922253.1 and AY922254.1),25 
and Japan (eg, mtDNA genome AP008249.1, AP008250.1, 
and AP008255.1),26 even though these studies failed to identify 
the coexistence and treated as to completely separated lineages.
discussion
In this study, we applied mitochondrial whole-genome rese-
quencing to investigate comprehensively the relationship of 
mitochondrial variations in tumor tissues and OS of NSCLC. 
Initially, we identified several mtDNA variations associated 
with the OS of NSCLC. Using unsupervised profiling, we 
identified two major substructures of mtDNA variations with 
the smaller substructure imbedded completely within the 
larger one. Follow-up manual curation revealed that these 
substructures represented two combinations of mtDNA hap-
logroups, including D/D4 and M/N, respectively, which are 
common in Asian populations, including Koreans.27,28 Smaller 
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figure 3. Kaplan–meier survival estimates of os among nsCLC 
according to mtDna haplogroups.
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figure 2. Population structure of mtDNA variations identified by 
unsupervised hierarchical clustering.  
Notes: the analysis was carried out by dChip software on 228 mtDna 
variations with minor variant frequency 2%, with row corresponding to 
individual variation and column representing individual nsCLC sample. 
Blue color circles are the mtDNA haplogroups manually identified with 
reference to mitochondrial phylogenetic tree build 9, released by  
20 July 2010 (www.phylotree.org).
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mtDNA substructure D/D4 and its imbedded substructure 
(D/D4/M/N) were significantly associated with worse OS of 
early-stage NSCLC. Thus, in the Korean population, specific 
mtDNA haplogroups but not individual mtDNA variations 
were associated with the worse OS of early-stage NSCLC. 
The association with haplogroup M/N seems to be driven by 
the imbedded haplogroup D/D4. This conclusion was further 
supported by the observation that the variation C9296T, 
a defining mutation of haplogroup D4b2b, which was a sub-
clade of haplogroup D4 on phylogenetic tree,23 had the stron-
gest association in individual variation analysis.
The observed haplogroup association might be driven, as 
least partially, by germline mutations in the studied popula-
tion. This finding is plausible because somatic mutations in 
cancer are random events and a haplogroup is a combination 
of variations at different locations of mtDNA genome that are 
transmitted together. As the associated haplogroup D/D4 is a 
common haplogroup in a normal Korean population27,28 and 
also a popular substructure in the tested NSCLC samples, it 
is not likely that somatic mutations establish simultaneously 
all of the defining variations in a large proportion of tumor 
tissues. Our analysis of somatic mutations by genotyping a 
subset of NSCLC patients supports this hypothesis. Actually, 
most of the tumor samples (66%), including those having hap-
logroup D/D4 and/or its parental haplogroup M/N, did not 
harbor any somatic mutations.
Moreover, all of 12 samples, having the majority of 
somatic mutations, had multiple somatic mutations in haplo-
group M/N (8 samples), D/D4 (2 samples), or both (2 samples); 
and 10 of 12 defining variations of haplogroups M/N and 
D/D4 were the most frequent sites for somatic mutations 
(4 per sample), comparing with median 1 somatic mutation 
per sample (range 0–11) for the entire genotyping dataset.19 
Furthermore, the somatic mutations occurred on the haplo-
groups M/N and D/D4 were characterized by complete or 
major turnover of the defining mutations in both directions. 
These findings not only suggest that haplogroups M/N and/or 
D/D4 were the hotspots for somatic mutations, but also 
suggest a more complicated mechanism of mtDNA somatic 
mutations other than the commonly accepted mechanism of 
sequential accumulation of mtDNA mutation.4
One of the major findings was the coexistence of all 
defining variations of mtDNA haplogroups M and N in 
majority of samples (56%), presuming common germline 
mutations in Koreans. According to the mitochondrial phy-
logenetic tree that uses haplogroups representing the major 
branch points, haplogroup M and N are two sibling super-
haplogroups that define out of Africa migration, as it is gen-
erally accepted that all mtDNA haplogroups found outside 
of Africa are descendants of either haplogroup N or its sib-
ling haplogroup M.27,29 The defining variations of two hap-
logroups should be mutually exclusive, which contradicts 
our sequencing results. In this study, of 211 samples having 
compete sequencing data on all defining mtDNA positions 
for haplogroup M and N, we found that 184 samples (87%) 
had identical sequences of either all or none of the defining 
variations, with rest of the samples having only one (12%) 
or two (1%) discrepancies. All samples had a complete vari-
ation profile of haplogroup H2a2a (Fig. 2) and its parent 
haplogroups (H2a2, H2a, H2, H, HV, and R0), which were 
subclades of haplogroup N; whereas the NSCLC outcome 
associated haplogroups D/D4 were the subclades of hap-
logroup M. In contrast to our findings, there has been no 
report on the coexistence of defining variations of haplo-
group M and N, even though we could identify the coexis-
tence from the published sequence data. It seems that there 
were some defects in the phylogenetic program with a built-
in algorithm that treated super-haplogroups as separated 
lineages. Therefore, a new phylogenetic program should be 
developed and mtDNA sequences should reassessed.
Except for variation T16362C, which was not associated 
with NSCLC outcome, all of the rest five defining variations of 
NSCLC sample
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figure 4. Distribution of germline vs. somatic mutations in a subset of 
nsCLC patients.  
Notes: the diagram was generated by dChip software on 103 mtDna 
variations from 64 patients who had provided the matched blood 
samples, with row corresponding to individual variation and column 
representing individual nsCLC sample. for each pair of sample, 
genotypes at each tested site were compared between tumor sample and 
matched blood sample. Gray/white color represents that nsCLC sample 
and blood sample had the same genotypes, suggesting that nsCLC 
sample had a germline allele at this site. White color represents that the 
paired samples had the same allele as the reference mtDna sequence 
(rCrs: revised Cambridge reference sequence of the Human 
mitochondrial Dna; GenBank: nC_012920); and gray color represents 
the variant allele. Blue/red color represents that nsCLC sample and 
blood sample had different genotypes, suggesting that nsCLC sample 
had a somatic mutation at this site. Blue color represent that the blood 
sample had the variant allele and the nsCLC sample had the reference 
allele. red color represent that the blood sample had the reference allele 
and the nsCLC sample had the variant allele. triangles at the bottom 
indicate the patients having the majority of somatic mutations.
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haplogroup D/D4 were located in the coding regions of mtDNA 
genome. Among them, variation C5178A and C8414T were 
non-synonymous variations (Table 2), resulting in amino acid 
substitutions in gene NADH dehydrogenase subunit 2 (Leu-
237Met) and ATP synthase F0 subunit 8 (Leu17Phe), respec-
tively. Variation G3010A was located in gene encoding region of 
16S ribosomal RNA. Several molecular epidemiological studies 
in Japanese population demonstrated that these variations were 
associated with longevity.30,31 Variation C5178A was associated 
with significantly higher serum levels of high-density lipopro-
tein cholesterol and lower blood triglyceride, which was prone to 
resist adult-onset diseases by suppressing obesity and atheroscle-
rosis in Japanese.32–34 However, other studies did not replicate 
the association of this variation with longevity in Chinese,35 but 
found the association with decreased longevity in the population 
of Costa Rica.36 A recent study replicated the association with 
longevity in Japanese, but pinpointed to a subclade haplogroup 
D4a.37 As the defining variations of haplogroup D4a had high 
associations with the previous reported variations, the previous 
reported longevity-association with C5178A and other varia-
tions might entirely due to population structure, which could 
not be replicated in other populations. It was possible that the 
observed association of haplogroup D/D4 with the worse OS 
in early-stage NSCLC patients was caused by genetic structures 
in the studied population, which were highly associated with 
unidentified causal mutations. On the other hand, the existence 
of highly associated mtDNA variations in different populations, 
which were characterized by differential distributions of specific 
haplogroups, created additional complexities for adjusting mul-
tiple comparisons and identifying causal mutations in associa-
tion studies. Additional population-based studies in a larger set 
of samples are needed to replicate our findings or further pin-
point to any subclade of mtDNA haplogroups. Moreover, follow 
up in vitro and in vivo functional experiments are also required 
to validate the results from populations.
A limitation of our study was the small sample size which 
prevented us to further assess the associations in the smaller 
haplogroups. We also did not find any association between 
mtDNA variations/haplogroups and the cancer recurrence, 
which could be explained by an even smaller sample set 
because we could not collect recurrence data from 43 (17%) 
NSCLC patients. Instead of investigating the whole-genome 
sequence, in this study, we could only examine somatic muta-
tions at limited variations sites on a subset of patients who 
had provided the matched blood samples. We observed that 
only a small proportion of tumor samples had harbored exten-
sive somatic mutations in certain hotspots with simultaneous 
turnover at defining sits of mtDNA haplogroups. However, 
we should pay special attentions to interpret and apply these 
results, even though there were no significant difference in 
demographic characters between this subset and the entire set 
of samples. In addition, the information on the cause of death 
was not available in this study.
Mitochondrial defects have long been suspected to play 
an important role in the development of cancer, and the 
human mtDNA genome has been completely sequenced to 
identify and characterize all encoded genes over a decade. To 
our knowledge, this is the first study of using mitochondrial 
whole-genome resequencing to investigate the associations 
of mitochondrial variations in tumor tissues with the clinical 
outcomes of NSCLC. Despite of its smaller size, the unique 
characters of mitochondrial genome, including maternally 
inherited pattern without recombination, multiple copies, and 
prone to mutations, require different genomic approaches to 
dissect the relationships between mtDNA variations and dis-
eases. Specifically, future research should address the inter-
actions between mtDNA variation and polymorphism on 
nuclear genome.
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